{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:35:45Z","timestamp":1790127345798,"version":"4.0.1"},"reference-count":123,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T00:00:00Z","timestamp":1648684800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Several pharmacotherapeutic interventions are available for maintenance treatment for opioid-related disorders. However, previous meta-analyses have been limited to pairwise comparisons of these interventions, and their efficacy relative to all others remains unclear. Our objective was to unify findings from different healthcare practices and generate evidence to strengthen clinical treatment protocols for the most widely prescribed medications for opioid-use disorders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched Medline, EMBASE, PsycINFO, CENTRAL, and ClinicalTrials.gov for all relevant randomized controlled trials (RCT) from database inception to February 12, 2022. Primary outcome was treatment retention, and secondary outcome was opioid use measured by urinalysis. We calculated risk ratios (RR) and 95% credible interval (CrI) using Bayesian network meta-analysis (NMA) for available evidence. We assessed the credibility of the NMA using the Confidence in Network Meta-Analysis tool.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Seventy-nine RCTs met the inclusion criteria. Due to heterogeneity in measuring opioid use and reporting format between studies, we conducted NMA only for treatment retention. Methadone was the highest ranked intervention (Surface Under the Cumulative Ranking [SUCRA] = 0.901) in the network with control being the lowest (SUCRA = 0.000). Methadone was superior to buprenorphine for treatment retention (RR = 1.22; 95% CrI = 1.06\u20131.40) and buprenorphine superior to naltrexone (RR = 1.39; 95% CrI = 1.10\u20131.80). However, due to a limited number of high-quality trials, confidence in the network estimates of other treatment pairs involving naltrexone and slow-release oral morphine (SROM) remains low.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>All treatments had higher retention than the non-pharmacotherapeutic control group. However, additional high-quality RCTs are needed to estimate more accurately the extent of efficacy of naltrexone and SROM relative to other medications. For pharmacotherapies with established efficacy profiles, assessment of their long-term comparative effectiveness may be warranted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec005\">\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>\n                      This systematic review has been registered with PROSPERO (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.crd.york.ac.uk\/prospero\" xlink:type=\"simple\">https:\/\/www.crd.york.ac.uk\/prospero<\/jats:ext-link>\n                      ) (identifier\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?RecordID=256212\" xlink:type=\"simple\">CRD42021256212<\/jats:ext-link>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0266142","type":"journal-article","created":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T13:55:57Z","timestamp":1648734957000},"page":"e0266142","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":52,"title":["Relative effectiveness of medications for opioid-related disorders: A systematic review and network meta-analysis of randomized controlled trials"],"prefix":"10.1371","volume":"17","author":[{"given":"Jihoon","family":"Lim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1856-9057","authenticated-orcid":true,"given":"Imen","family":"Farhat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6005-4006","authenticated-orcid":true,"given":"Antonios","family":"Douros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4756-1721","authenticated-orcid":true,"given":"Dimitra","family":"Panagiotoglou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,3,31]]},"reference":[{"issue":"Suppl","key":"pone.0266142.ref001","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/j.drugalcdep.2004.08.003","article-title":"Association of alcohol and drug use disorders and completed suicide: an empirical review of cohort studies","volume":"76","author":"HC Wilcox","year":"2004","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"pone.0266142.ref002","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2471\/BLT.12.108282","article-title":"Mortality among people who inject drugs: a systematic review and meta-analysis","volume":"91","author":"BM Mathers","year":"2013","journal-title":"Bull World Health Organ"},{"issue":"9651","key":"pone.0266142.ref003","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/S0140-6736(08)61311-2","article-title":"Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review","volume":"372","author":"BM Mathers","year":"2008","journal-title":"Lancet"},{"issue":"12","key":"pone.0266142.ref004","doi-asserted-by":"crossref","first-page":"e1192","DOI":"10.1016\/S2214-109X(17)30375-3","article-title":"Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review","volume":"5","author":"L Degenhardt","year":"2017","journal-title":"Lancet Glob Health"},{"issue":"6","key":"pone.0266142.ref005","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S2468-1253(19)30085-8","article-title":"The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study","volume":"4","author":"A Trickey","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10208","key":"pone.0266142.ref006","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/S0140-6736(19)32229-9","article-title":"Global patterns of opioid use and dependence: harms to populations, interventions, and future action","volume":"394","author":"L Degenhardt","year":"2019","journal-title":"Lancet"},{"key":"pone.0266142.ref007","author":"Centre for Addiction and Mental Health","year":"2016","journal-title":"Opioid Agonist Therapy Toronto, ON"},{"issue":"2","key":"pone.0266142.ref008","doi-asserted-by":"crossref","first-page":"e1920622","DOI":"10.1001\/jamanetworkopen.2019.20622","article-title":"Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder","volume":"3","author":"SE Wakeman","year":"2020","journal-title":"JAMA Netw Open"},{"key":"pone.0266142.ref009","doi-asserted-by":"crossref","first-page":"j1550","DOI":"10.1136\/bmj.j1550","article-title":"Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies","volume":"357","author":"L Sordo","year":"2017","journal-title":"BMJ"},{"key":"pone.0266142.ref010","first-page":"2","article-title":"The Impact of Methadone Maintenance Treatment on HIV Risk Behaviors among High-Risk Injection Drug Users: A Systematic Review","author":"P Karki","year":"2016","journal-title":"Evid Based Med Public Health"},{"key":"pone.0266142.ref011","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.drugalcdep.2018.12.018","article-title":"Opioid agonist treatment and the process of injection drug use initiation","volume":"197","author":"ML Mittal","year":"2019","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"pone.0266142.ref012","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13011-017-0126-1","article-title":"History of medication-assisted treatment and its association with initiating others into injection drug use in San Diego, CA","volume":"12","author":"ML Mittal","year":"2017","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"pone.0266142.ref013","doi-asserted-by":"crossref","first-page":"m772","DOI":"10.1136\/bmj.m772","article-title":"Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: population based retrospective cohort study","volume":"368","author":"LA Pearce","year":"2020","journal-title":"BMJ"},{"key":"pone.0266142.ref014","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.drugpo.2019.01.020","article-title":"Comparing Canadian and United States opioid agonist therapy policies","volume":"74","author":"KC Priest","year":"2019","journal-title":"Int J Drug Policy"},{"issue":"18","key":"pone.0266142.ref015","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1080\/14656566.2017.1409722","article-title":"Recommendations for buprenorphine and methadone therapy in opioid use disorder: a European consensus","volume":"18","author":"M Dematteis","year":"2017","journal-title":"Expert Opin Pharmacother"},{"key":"pone.0266142.ref016","volume-title":"Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence","author":"World Health Organization","year":"2009"},{"issue":"9","key":"pone.0266142.ref017","doi-asserted-by":"crossref","first-page":"E247","DOI":"10.1503\/cmaj.170958","article-title":"Management of opioid use disorders: a national clinical practice guideline","volume":"190","author":"J Bruneau","year":"2018","journal-title":"CMAJ"},{"issue":"5","key":"pone.0266142.ref018","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/ADM.0000000000000166","article-title":"American Society of Addiction Medicine (ASAM) National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use","volume":"9","author":"K Kampman","year":"2015","journal-title":"J Addict Med"},{"issue":"7","key":"pone.0266142.ref019","first-page":"1188","volume":"113","author":"BP Jarvis","year":"2018","journal-title":"Extended-release"},{"issue":"4","key":"pone.0266142.ref020","first-page":"CD001333","article-title":"Oral naltrexone maintenance treatment for opioid dependence","author":"S Minozzi","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"pone.0266142.ref021","doi-asserted-by":"crossref","first-page":"e025799","DOI":"10.1136\/bmjopen-2018-025799","article-title":"Slow release oral morphine versus methadone for the treatment of opioid use disorder","volume":"9","author":"J Klimas","year":"2019","journal-title":"BMJ Open"},{"issue":"6","key":"pone.0266142.ref022","first-page":"CD009879","article-title":"Slow-release oral morphine as maintenance therapy for opioid dependence","author":"M Ferri","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"pone.0266142.ref023","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1111\/j.1365-2125.2011.03923.x","article-title":"Slow-release oral morphine for opioid maintenance treatment: a systematic review","volume":"71","author":"J Jegu","year":"2011","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"pone.0266142.ref024","first-page":"CD002207","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","author":"RP Mattick","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"pone.0266142.ref025","first-page":"CD002209","article-title":"Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence","author":"RP Mattick","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"pone.0266142.ref026","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"B Hutton","year":"2015","journal-title":"Ann Intern Med"},{"issue":"12","key":"pone.0266142.ref027","doi-asserted-by":"crossref","first-page":"e0244401","DOI":"10.1371\/journal.pone.0244401","article-title":"Evaluating comparative effectiveness of psychosocial interventions adjunctive to opioid agonist therapy for opioid use disorder: A systematic review with network meta-analyses","volume":"15","author":"D Rice","year":"2020","journal-title":"PLoS One"},{"key":"pone.0266142.ref028","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/2046-4053-1-10","article-title":"Evidence summaries: the evolution of a rapid review approach","volume":"1","author":"S Khangura","year":"2012","journal-title":"Syst Rev"},{"key":"pone.0266142.ref029","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"JAC Sterne","year":"2019","journal-title":"BMJ"},{"issue":"2","key":"pone.0266142.ref030","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/jrsm.1049","article-title":"Accounting for correlation in network meta-analysis with multi-arm trials","volume":"3","author":"AJ Franchini","year":"2012","journal-title":"Res Synth Methods"},{"issue":"2","key":"pone.0266142.ref031","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jval.2014.01.004","article-title":"Indirect treatment comparison\/network meta-analysis study questionnaire to assess relevance and credibility to inform health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force report","volume":"17","author":"JP Jansen","year":"2014","journal-title":"Value Health"},{"issue":"4","key":"pone.0266142.ref032","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/1467-9868.00353","article-title":"Bayesian measures of model complexity and fit","volume":"64","author":"DJ Spiegelhalter","year":"2002","journal-title":"Journal of the royal statistical society: Series b (statistical methodology)"},{"issue":"4","key":"pone.0266142.ref033","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1080\/10618600.1998.10474787","article-title":"General methods for monitoring convergence of iterative simulations","volume":"7","author":"SP Brooks","year":"1998","journal-title":"Journal of computational and graphical statistics"},{"issue":"4","key":"pone.0266142.ref034","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1214\/ss\/1177011136","article-title":"Inference from iterative simulation using multiple sequences","volume":"7","author":"A Gelman","year":"1992","journal-title":"Statistical science"},{"issue":"2","key":"pone.0266142.ref035","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"G Salanti","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"pone.0266142.ref036","doi-asserted-by":"crossref","first-page":"e1003082","DOI":"10.1371\/journal.pmed.1003082","article-title":"CINeMA: An approach for assessing confidence in the results of a network meta-analysis","volume":"17","author":"A Nikolakopoulou","year":"2020","journal-title":"PLoS Med"},{"key":"pone.0266142.ref037","author":"NC Clark","year":"2006","journal-title":"Expanding the Options for the Treatment of Heroin Dependence with Oral Supervised Opioid Substitution Therapy: LAAM, Buprenorphine and Slow Release Oral Morphine as Alternatives to Methadone: University of Melbourne, Department of Medicine, St Vincent\u2019s Hospital"},{"key":"pone.0266142.ref038","first-page":"67","article-title":"Patient response to naltrexone: issues of acceptance, treatment effects, and frequency of administration","volume":"9","author":"S Curran","year":"1976","journal-title":"NIDA Research Monograph"},{"issue":"10","key":"pone.0266142.ref039","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1056\/NEJMoa022164","article-title":"Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone","volume":"349","author":"PJ Fudala","year":"2003","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"pone.0266142.ref040","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jsat.2006.05.005","article-title":"Naltrexone with or without fluoxetine for preventing relapse to heroin addiction in St. Petersburg, Russia","volume":"31","author":"EM Krupitsky","year":"2006","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"SUPPL. 1","key":"pone.0266142.ref041","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1080\/10550490490440799","article-title":"Implementing Buprenorphine Treatment in Community Settings in Australia: Experiences from the Buprenorphine Implementation Trial","volume":"13","author":"N Lintzeris","year":"2004","journal-title":"American Journal on Addictions"},{"key":"pone.0266142.ref042","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2019.107680","article-title":"Methadone treatment of arrestees: A randomized clinical trial","volume":"206","author":"RP Schwartz","year":"2020","journal-title":"Drug and Alcohol Dependence"},{"issue":"21","key":"pone.0266142.ref043","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1016\/j.lfs.2005.05.036","article-title":"Naltrexone plus benzodiazepine aids abstinence in opioid-dependent patients","volume":"77","author":"L Stella","year":"2005","journal-title":"Life Sciences"},{"issue":"3","key":"pone.0266142.ref044","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0740-5472(03)00024-2","article-title":"Methadone versus buprenorphine maintenance for the treatment of heroin-dependent outpatients","volume":"24","author":"J. Ahmadi","year":"2003","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"9","key":"pone.0266142.ref045","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1046\/j.1365-2362.2003.01218.x","article-title":"Controlled, randomized trial in maintenance treatment of intravenous buprenorphine dependence with naltrexone, methadone or buprenorphine: A novel study","volume":"33","author":"J Ahmadi","year":"2003","journal-title":"European Journal of Clinical Investigation"},{"issue":"1","key":"pone.0266142.ref046","first-page":"23","article-title":"Treatment of intravenous buprenorphine dependence. A randomized open clinical trial","volume":"6","author":"J Ahmadi","year":"2003","journal-title":"German Journal of Psychiatry"},{"issue":"4","key":"pone.0266142.ref047","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/add.12440","article-title":"Maintenance treatment for opioid dependence with slow-release oral morphine: a randomized cross-over, non-inferiority study versus methadone","volume":"109","author":"T Beck","year":"2014","journal-title":"Addiction (Abingdon, England)"},{"issue":"1","key":"pone.0266142.ref048","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/clpt.1988.13","article-title":"A clinical trial of buprenorphine: Comparison with methadone in the detoxification of heroin addicts","volume":"43","author":"WK Bickel","year":"1988","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"4","key":"pone.0266142.ref049","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1211\/ijpp.14.4.0003","article-title":"Pilot randomised controlled trial of community pharmacy administration of buprenorphine versus methadone","volume":"14","author":"IM Cameron","year":"2006","journal-title":"International Journal of Pharmacy Practice"},{"issue":"2","key":"pone.0266142.ref050","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1001\/archpsyc.63.2.210","article-title":"Injectable, sustained-release naltrexone for the treatment of opioid dependence: A randomized, placebo-controlled trial","volume":"63","author":"SD Comer","year":"2006","journal-title":"Archives of General Psychiatry"},{"issue":"6","key":"pone.0266142.ref051","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0740-5472(97)00020-2","article-title":"Naltrexone pharmacotherapy for opioid dependent federal probationers","volume":"14","author":"JW Cornish","year":"1997","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"5","key":"pone.0266142.ref052","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/j.1521-0391.2010.00070.x","article-title":"A randomized trial of oral naltrexone for treating opioid-dependent offenders","volume":"19","author":"DM Coviello","year":"2010","journal-title":"The American Journal on Addictions"},{"issue":"3","key":"pone.0266142.ref053","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.drugalcdep.2011.06.021","article-title":"Results of a pilot randomized controlled trial of buprenorphine for opioid dependent women in the criminal justice system","volume":"119","author":"KL Cropsey","year":"2011","journal-title":"Drug and Alcohol Dependence"},{"issue":"16","key":"pone.0266142.ref054","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1001\/jama.2015.3474","article-title":"Emergency department-initiated buprenorphine\/naloxone treatment for opioid dependence: A randomized clinical trial","volume":"313","author":"G D\u2019Onofrio","year":"2015","journal-title":"JAMA\u2014Journal of the American Medical Association"},{"key":"pone.0266142.ref055","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.drugalcdep.2017.01.016","article-title":"Effectiveness and cost-effectiveness of unsupervised buprenorphine-naloxone for the treatment of heroin dependence in a randomized waitlist controlled trial","volume":"174","author":"AJ Dunlop","year":"2017","journal-title":"Drug and Alcohol Dependence"},{"issue":"8","key":"pone.0266142.ref056","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1111\/j.1360-0443.2005.001128.x","article-title":"Comparative study of the effectiveness of slow-release morphine and methadone for opioid maintenance therapy","volume":"100","author":"H Eder","year":"2005","journal-title":"Addiction"},{"issue":"9","key":"pone.0266142.ref057","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1046\/j.1360-0443.1999.94913376.x","article-title":"Buprenorphine versus methadone maintenance for the treatment of opioid dependence","volume":"94","author":"G Fischer","year":"1999","journal-title":"Addiction"},{"issue":"1\u20133","key":"pone.0266142.ref058","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.drugalcdep.2007.11.021","article-title":"A randomized trial of 6-month methadone maintenance with standard or minimal counseling versus 21-day methadone detoxification","volume":"94","author":"VA Gruber","year":"2008","journal-title":"Drug and Alcohol Dependence"},{"issue":"4","key":"pone.0266142.ref059","first-page":"2","article-title":"Efficacy of naltrexone hydrochloride for preventing relapse among opiate-dependent patients after detoxification","volume":"11","author":"S Guo","year":"2001","journal-title":"Hong Kong Journal of Psychiatry"},{"issue":"10173","key":"pone.0266142.ref060","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S0140-6736(18)32259-1","article-title":"Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"393","author":"BR Haight","year":"2019","journal-title":"The Lancet"},{"issue":"3","key":"pone.0266142.ref061","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1001\/archpsyc.1978.01770270085008","article-title":"Clinical evaluation of naltrexone treatment of opiate-dependent individuals","volume":"35","author":"LE Hollister","year":"1978","journal-title":"Archives of General Psychiatry"},{"key":"pone.0266142.ref062","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.drugalcdep.2018.12.026","article-title":"The effects of extended-release injectable naltrexone and incentives for opiate abstinence in heroin-dependent adults in a model therapeutic workplace: A randomized trial","volume":"197","author":"BP Jarvis","year":"2019","journal-title":"Drug and Alcohol Dependence"},{"issue":"18","key":"pone.0266142.ref063","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1056\/NEJM200011023431802","article-title":"A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence","volume":"343","author":"RE Johnson","year":"2000","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"pone.0266142.ref064","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/0376-8716(95)01186-2","article-title":"A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence","volume":"40","author":"RE Johnson","year":"1995","journal-title":"Drug and Alcohol Dependence"},{"issue":"20","key":"pone.0266142.ref065","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1001\/jama.1992.03480200058024","article-title":"A controlled trial of buprenorphine treatment for opioid dependence","volume":"267","author":"RE Johnson","year":"1992","journal-title":"Journal of the American Medical Association"},{"issue":"9358","key":"pone.0266142.ref066","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S0140-6736(03)12600-1","article-title":"1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: A randomised, placebo-controlled trial","volume":"361","author":"J Kakko","year":"2003","journal-title":"Lancet"},{"issue":"5","key":"pone.0266142.ref067","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1176\/ajp.2007.164.5.797","article-title":"A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: A randomized controlled trial","volume":"164","author":"J Kakko","year":"2007","journal-title":"American Journal of Psychiatry"},{"issue":"4","key":"pone.0266142.ref068","first-page":"5","article-title":"Buprenorphine-naloxone versus methadone maintenance therapy: A randomised double-blind trial with opioid-dependent patients","volume":"10","author":"JB Kamien","year":"2008","journal-title":"Heroin Addiction and Related Clinical Problems"},{"issue":"3","key":"pone.0266142.ref069","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jsat.2009.03.002","article-title":"A randomized clinical trial of methadone maintenance for prisoners: Results at 12 months postrelease","volume":"37","author":"TW Kinlock","year":"2009","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"2","key":"pone.0266142.ref070","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1016\/S2352-3018(20)30302-7","article-title":"HIV clinic-based buprenorphine plus naloxone versus referral for methadone maintenance therapy for treatment of opioid use disorder in HIV clinics in Vietnam (BRAVO): an open-label, randomised, non-inferiority trial.","volume":"8","author":"PT Korthuis","year":"2021","journal-title":"The Lancet HIV"},{"issue":"6","key":"pone.0266142.ref071","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/00005053-199306000-00004","article-title":"Buprenorphine versus methadone maintenance for opioid dependence","volume":"181","author":"TR Kosten","year":"1993","journal-title":"Journal of Nervous and Mental Disease"},{"issue":"2","key":"pone.0266142.ref072","first-page":"148","article-title":"Buprenorphine and methadone to opiate addicts\u2014a randomized trial","volume":"125","author":"\u00d8 Kristensen","year":"2005","journal-title":"Tidsskrift for den Norske laegeforening"},{"issue":"5","key":"pone.0266142.ref073","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1046\/j.1360-0443.2002.00090.x","article-title":"A placebo-controlled study of high dose buprenorphine in opiate dependents waiting for medication-assisted rehabilitation in Oslo, Norway","volume":"97","author":"AL Krook","year":"2002","journal-title":"Addiction"},{"issue":"9776","key":"pone.0266142.ref074","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/S0140-6736(11)60358-9","article-title":"Injectable extended-release naltrexone for opioid dependence: A double-blind, placebo-controlled, multicentre randomised trial","volume":"377","author":"E Krupitsky","year":"2011","journal-title":"The Lancet"},{"issue":"3","key":"pone.0266142.ref075","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.drugalcdep.2013.04.021","article-title":"Naltrexone with or without guanfacine for preventing relapse to opiate addiction in St.-Petersburg","volume":"132","author":"E Krupitsky","year":"2013","journal-title":"Russia. Drug and Alcohol Dependence"},{"issue":"9","key":"pone.0266142.ref076","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1001\/archgenpsychiatry.2012.1a","article-title":"Randomized trial of long-acting sustained-release naltrexone implant vs oral naltrexone or placebo for preventing relapse to opioid dependence","volume":"69","author":"E Krupitsky","year":"2012","journal-title":"Archives of General Psychiatry"},{"issue":"4","key":"pone.0266142.ref077","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jsat.2004.02.002","article-title":"Naltrexone for heroin dependence treatment in St. Petersburg, Russia","volume":"26","author":"EM Krupitsky","year":"2004","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"13","key":"pone.0266142.ref078","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1056\/NEJMoa1505409","article-title":"Extended-release naltrexone to prevent opioid relapse in criminal justice offenders","volume":"374","author":"JD Lee","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"pone.0266142.ref079","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1111\/add.12894","article-title":"Opioid treatment at release from jail using extended-release naltrexone: a pilot proof-of-concept randomized effectiveness trial","volume":"110","author":"JD Lee","year":"2015","journal-title":"Addiction (Abingdon, England)"},{"issue":"10118","key":"pone.0266142.ref080","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","article-title":"Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial","volume":"391","author":"JD Lee","year":"2018","journal-title":"The Lancet"},{"issue":"1","key":"pone.0266142.ref081","first-page":"36","article-title":"A Naltrexone double blind placebo controlled study in Israel","volume":"29","author":"A Lerner","year":"1992","journal-title":"Israel Journal of Psychiatry and Related Sciences"},{"issue":"14","key":"pone.0266142.ref082","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1001\/jama.2010.1427","article-title":"Buprenorphine implants for treatment of opioid dependence: A randomized controlled trial","volume":"304","author":"W Ling","year":"2010","journal-title":"JAMA\u2014Journal of the American Medical Association"},{"issue":"5","key":"pone.0266142.ref083","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1001\/archpsyc.1996.01830050035005","article-title":"A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence","volume":"53","author":"W Ling","year":"1996","journal-title":"Archives of General Psychiatry"},{"issue":"9","key":"pone.0266142.ref084","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1111\/j.1360-0443.2009.02653.x","article-title":"A double-blind, randomized, parallel group study to compare the efficacy, safety and tolerability of slow-release oral morphine versus methadone in opioid-dependent in-patients willing to undergo detoxification","volume":"104","author":"E Madlung-Kratzer","year":"2009","journal-title":"Addiction"},{"issue":"1\u20133","key":"pone.0266142.ref085","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.drugalcdep.2008.08.006","article-title":"Buprenorphine and methadone maintenance in jail and post-release: A randomized clinical trial","volume":"99","author":"S Magura","year":"2009","journal-title":"Drug and Alcohol Dependence"},{"issue":"4","key":"pone.0266142.ref086","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1046\/j.1360-0443.2003.00335.x","article-title":"Buprenorphine versus methadone maintenance therapy: A randomized double-blind trial with 405 opioid-dependent patients","volume":"98","author":"RP Mattick","year":"2003","journal-title":"Addiction"},{"issue":"5","key":"pone.0266142.ref087","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1111\/add.13259","article-title":"Medical treatments for opioid use disorder in Iran: a randomized, double-blind placebo-controlled comparison of buprenorphine\/naloxone and naltrexone maintenance treatment","volume":"111","author":"A Mokri","year":"2016","journal-title":"Addiction (Abingdon, England)"},{"issue":"3","key":"pone.0266142.ref088","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1007\/s00213-005-2239-x","article-title":"Randomized clinical trial to compare the effects of methadone and buprenorphine on the immune system in drug abusers","volume":"179","author":"S Neri","year":"2005","journal-title":"Psychopharmacology"},{"issue":"1","key":"pone.0266142.ref089","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/10550887.2019.1690929","article-title":"Randomized clinical trial comparing buprenorphine\/naloxone and methadone for the treatment of patients with failed back surgery syndrome and opioid addiction","volume":"38","author":"AM Neumann","year":"2020","journal-title":"Journal of Addictive Diseases"},{"issue":"1","key":"pone.0266142.ref090","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1080\/10550887.2012.759872","article-title":"A preliminary study comparing methadone and buprenorphine in patients with chronic pain and coexistent opioid addiction","volume":"32","author":"AM Neumann","year":"2013","journal-title":"Journal of Addictive Diseases"},{"issue":"8141","key":"pone.0266142.ref091","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0140-6736(79)91550-2","article-title":"Double-blind comparison of methadone and placebo maintenance treatments of narcotic addicts in Hong Kong","volume":"2","author":"RG Newman","year":"1979","journal-title":"Lancet (london, england)"},{"issue":"9","key":"pone.0266142.ref092","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1001\/archpsyc.56.9.812","article-title":"Desipramine in opioid-dependent cocaine abusers maintained on buprenorphine vs methadone","volume":"56","author":"AH Oliveto","year":"1999","journal-title":"Archives of General Psychiatry"},{"issue":"1\u20133","key":"pone.0266142.ref093","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.drugalcdep.2011.06.012","article-title":"Drug use and HIV risk outcomes in opioid-injecting men in the Republic of Georgia: Behavioral treatment+naltrexone compared to usual care","volume":"120","author":"D Otiashvili","year":"2012","journal-title":"Drug and Alcohol Dependence"},{"issue":"2","key":"pone.0266142.ref094","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.drugalcdep.2013.06.024","article-title":"Methadone and buprenorphine-naloxone are effective in reducing illicit buprenorphine and other opioid use, and reducing HIV risk behavior\u2014outcomes of a randomized trial","volume":"133","author":"D Otiashvili","year":"2013","journal-title":"Drug and alcohol dependence"},{"issue":"1","key":"pone.0266142.ref095","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0376-8716(00)80006-X","article-title":"Buprenorphine: A controlled clinical trial in the treatment of opioid dependence","volume":"60","author":"PP Pani","year":"2000","journal-title":"Drug and Alcohol Dependence"},{"issue":"1","key":"pone.0266142.ref096","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0376-8716(00)00163-0","article-title":"Double-blind randomized trial of buprenorphine and methadone in opiate dependence","volume":"62","author":"S Petitjean","year":"2001","journal-title":"Drug and Alcohol Dependence"},{"issue":"12","key":"pone.0266142.ref097","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1111\/add.12315","article-title":"Buprenorphine implants for treatment of opioid dependence: randomized comparison to placebo and sublingual buprenorphine\/naloxone","volume":"108","author":"RN Rosenthal","year":"2013","journal-title":"Addiction (Abingdon, England)"},{"issue":"8","key":"pone.0266142.ref098","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1111\/j.1360-0443.1991.tb01859.x","article-title":"Follow-up after a six-month maintenance period on naltrexone versus placebo in heroin addicts","volume":"86","author":"L San","year":"1991","journal-title":"British Journal of Addiction"},{"issue":"1\u20132","key":"pone.0266142.ref099","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.drugalcdep.2012.08.002","article-title":"Buprenorphine\/Naloxone and methadone effects on laboratory indices of liver health: A randomized trial","volume":"128","author":"AJ Saxon","year":"2013","journal-title":"Drug and Alcohol Dependence"},{"issue":"9631","key":"pone.0266142.ref100","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1016\/S0140-6736(08)60954-X","article-title":"Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double-blind, placebo-controlled trial","volume":"371","author":"RS Schottenfeld","year":"2008","journal-title":"The Lancet"},{"issue":"2","key":"pone.0266142.ref101","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1176\/appi.ajp.162.2.340","article-title":"Methadone versus buprenorphine with contingency management or performance feedback for cocaine and opioid dependence","volume":"162","author":"RS Schottenfeld","year":"2005","journal-title":"American Journal of Psychiatry"},{"issue":"8","key":"pone.0266142.ref102","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1001\/archpsyc.1997.01830200041006","article-title":"Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse","volume":"54","author":"RS Schottenfeld","year":"1997","journal-title":"Archives of General Psychiatry"},{"issue":"1","key":"pone.0266142.ref103","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1001\/archpsyc.63.1.102","article-title":"A randomized controlled trial of interim methadone maintenance","volume":"63","author":"RP Schwartz","year":"2006","journal-title":"Archives of General Psychiatry"},{"issue":"5","key":"pone.0266142.ref104","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1055\/s-2002-34115","article-title":"Detoxification of opiate addicts with multiple drug abuse: A comparison of buprenorphine vs. methadone","volume":"35","author":"J Seifert","year":"2002","journal-title":"Pharmacopsychiatry"},{"issue":"12","key":"pone.0266142.ref105","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/0006-3223(94)91240-8","article-title":"The efficacy of Naltrexone in preventing reabuse of heroin after detoxification","volume":"35","author":"EN Shufman","year":"1994","journal-title":"Biological Psychiatry"},{"issue":"5","key":"pone.0266142.ref106","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1017\/S146114570700836X","article-title":"Retention rate and substance use in methadone and buprenorphine maintenance therapy and predictors of outcome: Results from a randomized study","volume":"11","author":"M Soyka","year":"2008","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"4","key":"pone.0266142.ref107","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/BF02247469","article-title":"Buprenorphine versus methadone in the treatment of opioid-dependent cocaine users","volume":"116","author":"EC Strain","year":"1994","journal-title":"Psychopharmacology"},{"issue":"7","key":"pone.0266142.ref108","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1176\/ajp.151.7.1025","article-title":"Comparison of buprenorphine and methadone in the treatment of opioid dependence","volume":"151","author":"EC Strain","year":"1994","journal-title":"American Journal of Psychiatry"},{"key":"pone.0266142.ref109","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.drugalcdep.2014.11.028","article-title":"Opioid use and dropout in patients receiving oral naltrexone with or without single administration of injection naltrexone","volume":"147","author":"MA Sullivan","year":"2015","journal-title":"Drug and Alcohol Dependence"},{"issue":"12","key":"pone.0266142.ref110","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/jamapsychiatry.2017.3206","article-title":"Effectiveness of injectable extended-release naltrexone vs daily buprenorphine-naloxone for opioid dependence: A randomized clinical noninferiority trial","volume":"74","author":"L Tanum","year":"2017","journal-title":"JAMA Psychiatry"},{"issue":"5","key":"pone.0266142.ref111","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1176\/appi.ajp.2011.11071121","article-title":"Naltrexone implant for the treatment of polydrug dependence: A randomized controlled trial","volume":"169","author":"J Tiihonen","year":"2012","journal-title":"American Journal of Psychiatry"},{"key":"pone.0266142.ref112","article-title":"Treatment of opioid dependence with buprenorphine\/naloxone sublingual tablets: a phase 3 randomized, double-blind, placebo-controlled trial","author":"X Wang","year":"2018","journal-title":"Asia-pacific psychiatry"},{"issue":"593","key":"pone.0266142.ref113","doi-asserted-by":"crossref","first-page":"e772","DOI":"10.3399\/bjgp11X613106","article-title":"Comparison of methadone and buprenorphine for opiate detoxification (LEEDS trial): a randomised controlled trial","volume":"61","author":"NM Wright","year":"2011","journal-title":"British journal of general practice"},{"issue":"9","key":"pone.0266142.ref114","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.2105\/AJPH.81.9.1185","article-title":"A randomized trial of an interim methadone maintenance clinic","volume":"81","author":"SR Yancovitz","year":"1991","journal-title":"American Journal of Public Health"},{"issue":"8","key":"pone.0266142.ref115","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1111\/add.15399","article-title":"Behavioral counseling and abstinence-contingent take-home buprenorphine in general practitioners\u2019 offices in Malaysia: a randomized, open-label clinical trial","volume":"116","author":"RS Schottenfeld","year":"2021","journal-title":"Addiction"},{"key":"pone.0266142.ref116","volume-title":"A Guideline for the Clinical Management of Opioid Use Disorder","author":"British Columbia Centre on Substance Use","year":"2017"},{"issue":"4","key":"pone.0266142.ref117","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.jval.2011.04.002","article-title":"Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1","volume":"14","author":"JP Jansen","year":"2011","journal-title":"Value Health"},{"issue":"2","key":"pone.0266142.ref118","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1080\/02791072.2015.1014948","article-title":"Changes in Quality of Life following Buprenorphine Treatment: Relationship with Treatment Retention and Illicit Opioid Use","volume":"47","author":"SG Mitchell","year":"2015","journal-title":"J Psychoactive Drugs"},{"issue":"3","key":"pone.0266142.ref119","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/01.pra.0000351884.83377.e2","article-title":"Benefits of retention in methadone maintenance and chronic medical conditions as risk factors for premature death among older heroin addicts","volume":"15","author":"A Fareed","year":"2009","journal-title":"J Psychiatr Pract"},{"issue":"10","key":"pone.0266142.ref120","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S2215-0366(15)00366-1","article-title":"Mortality risk of opioid substitution therapy with methadone versus buprenorphine: a retrospective cohort study","volume":"2","author":"J Kimber","year":"2015","journal-title":"Lancet Psychiatry"},{"issue":"8","key":"pone.0266142.ref121","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1111\/add.14188","article-title":"The impact of buprenorphine and methadone on mortality: a primary care cohort study in the United Kingdom","volume":"113","author":"M Hickman","year":"2018","journal-title":"Addiction"},{"issue":"3","key":"pone.0266142.ref122","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/M17-3107","article-title":"Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality: A Cohort Study","volume":"169","author":"MR Larochelle","year":"2018","journal-title":"Ann Intern Med"},{"issue":"4","key":"pone.0266142.ref123","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jsat.2005.02.007","article-title":"An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research","volume":"28","author":"L Amato","year":"2005","journal-title":"J Subst Abuse Treat"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0266142","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T06:59:48Z","timestamp":1726901988000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0266142"}},"subtitle":[],"editor":[{"given":"Surasak","family":"Saokaew","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,3,31]]},"references-count":123,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,3,31]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0266142","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,31]]}}}